Gefitinib
Products in Health Canada’s databases that list Gefitinib as a medicinal or active ingredient, under this spelling. The same substance can be listed under another name (a salt, a common name), which has its own page.
- Drug products
- 7
- 6 authorized now
- Natural health products
- 0
- 0 active licences
- Notices of Compliance
- 21
- Products in all
- 7
Drug products
Authorized products first.
| Name | DIN | Status | Holder | Status since |
|---|---|---|---|---|
| APO-GEFITINIB (250 MG) | 02468050 | Marketed | Apotex Inc. | |
| IRESSA (250 MG) | 02248676 | Marketed | Astrazeneca Canada Inc | |
| JAMP GEFITINIB (250 MG) | 02500663 | Marketed | JAMP Pharma Corporation | |
| AURO-GEFITINIB (250 MG) | 02533685 | Approved | Auro Pharma Inc. | |
| EUGIA-GEFITINIB (250 MG) | 02547546 | Approved | Eugia Pharma Inc. | |
| NAT-GEFITINIB (250 MG) | 02491796 | Dormant | Natco Pharma (Canada) Inc | |
| SANDOZ GEFITINIB (250 MG) | 02487748 | Cancelled Post Market | Sandoz Canada Inc. |
Notices of Compliance
Approvals of drug submissions that list it, newest first.
- EUGIA-GEFITINIBMay 8, 2024 · NOC 33189
- AURO-GEFITINIBJanuary 4, 2024 · NOC 32459
- JAMP GEFITINIBJanuary 26, 2023 · NOC 29991
- AURO-GEFITINIBDecember 16, 2022 · NOC 29719
- JAMP GEFITINIBMarch 15, 2022 · NOC 27766
- APO-GEFITINIBFebruary 1, 2022 · NOC 27514
- SANDOZ GEFITINIBNovember 4, 2021 · NOC 26967
- NAT-GEFITINIBOctober 25, 2021 · NOC 26909
- IRESSAApril 1, 2021 · NOC 25594
- JAMP-GEFITINIBJune 19, 2020 · NOC 23822
- NAT-GEFITINIBAugust 23, 2019 · NOC 22573
- SANDOZ GEFITINIBApril 23, 2019 · NOC 22086
- APO-GEFITINIBAugust 31, 2017 · NOC 19732
- IRESSAMarch 7, 2012 · NOC 13083
- IRESSADecember 18, 2009 · NOC 10885
- IRESSADecember 19, 2008 · NOC 9952
- IRESSANovember 30, 2007 · NOC 9213
- IRESSAJuly 18, 2006 · NOC 8151
- IRESSAJune 26, 2006 · NOC 8075
- IRESSAMay 3, 2006 · NOC 7920
- IRESSADecember 17, 2003 · NOC 925